CTOs on the Move


 
CrescentCare is an organization of health and wellness centers that is responding to the need for broader healthcare services in the Greater New Orleans area. CrescentCare uses proven interventions and evidence-based practices to improve outcomes for i...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

International Isotopes

International Isotopes is a Idaho Falls, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wave Life Sciences

WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.

Medical Practice Management Associates

Medical Practice Management Associates is a Vineland, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

B-Line Medical

B-Line Medical is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.